CD19 CAR T shows immune reboot in small MS trial, Cell reports

EricTopol · x · 2026-11-20

Eric Topol highlights a Cell paper on CD19 CAR T (milocabtagene autoleucel) in MS: 5 patients (2 progressive, 3 relapsing) showed more than B-cell depletion — an immune system reboot with naive-phenotype B cell repopulation at month 6, CSF signature changes, and stable disease parameters with declining NfL/GFAP at 12–24 months.

Original post →

More from Research

Research channel →